Table 1. Baseline Demographic Data for Cohort and Most Common Cancer Typesa.
| Tissue | No. | Median (PR), y | Age, mean (SD), y | No. (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Female Sex | Race | Treatment | ||||||||
| Survival | Follow-up | White | Black | Other | Surgery | Radiation Therapy | ||||
| Prostate | 206 889 | 9.9 (9.9-10.0) | 6 (1-19) | 69.1 (9.7) | 0 | 156 909 (75.8) | 33 755 (16.3) | 14 652 (7.1) | 99 250 (48.0) | 69 813 (33.7) |
| Localized | 110 187 | 14.7 (14.6-14.8) | 7 (1-16) | 66.7 (9.5) | 0 | 79 745 (72.4) | 20 152 (18.3) | 8982 (8.2) | 44 796 (40.7) | 43 274 (39.3) |
| Metastatic | 5005 | 2.1 (2.0-2.2) | 2 (0-10) | 72.1 (11.1) | 0 | 3219 (64.3) | 1168 (23.3) | 606 (12.1) | 676 (13.5) | 1196 (23.9) |
| Lung and bronchus | 190 488 | 0.8 (0.8-0.8) | 1 (0-11) | 66 (11.3) | 73 742 (38.7) | 153 457 (80.6) | 24 226 (12.7) | 12 681 (6.7) | 52 773 (27.7) | 92 632 (48.6) |
| Localized | 52 080 | 2.0 (2.0-2.1) | 2 (0-14) | 67.4 (10.8) | 23 950 (46.0) | 41 295 (79.3) | 6578 (12.6) | 4178 (8.0) | 26 390 (50.7) | 22 232 (42.7) |
| Metastatic | 56 136 | 0.5 (0.5-0.5) | 0 (0-3) | 66.5 (11.4) | 24 544 (43.7) | 42 511 (75.7) | 8610 (15.3) | 4997 (8.9) | 4737 (8.4) | 28 788 (51.3) |
| Breast | 188 751 | 14.7 (14.5-14.8) | 9 (1-27) | 60.6 (14.2) | 187 328 (99.2) | 163 802 (86.8) | 22 307 (11.8) | 2098 (1.1) | 176 824 (93.7) | 68 451 (36.3) |
| Localized | 171 618 | 16.1 (16.0-16.2) | 10 (1-27) | 60.3 (14.0) | 170 387 (99.3) | 149 508 (87.1) | 19 809 (11.5) | 1843 (1.1) | 167 034 (97.3) | 62 962 (36.7) |
| Metastatic | 10 111 | 1.8 (1.8-1.9) | 2 (0-12) | 62.9 (14.2) | 10 007 (99.0) | 8319 (82.3) | 1679 (16.6) | 95 (0.9) | 5909 (58.4) | 3904 (38.6) |
| Colon | 172 769 | 5.3 (5.3-5.4) | 4 (0-23) | 69.2 (12.5) | 88 094 (51.0) | 144 501 (83.6) | 15 730 (9.1) | 12 197 (7.1) | 156 886 (90.8) | 8001 (4.6) |
| Localized | 132 472 | 8.3 (8.2-8.4) | 6 (0-25) | 69.3 (12.3) | 67 536 (51.0) | 111 117 (83.9) | 11 148 (8.4) | 9932 (7.5) | 129 891 (98.1) | 5285 (4.0) |
| Metastatic | 32 307 | 0.8 (0.8-0.8) | 1 (0-6) | 67.6 (12.9) | 16 170 (50.1) | 26 645 (82.5) | 3659 (11.3) | 1987 (6.2) | 23 936 (74.1) | 2331 (7.2) |
| All cancers | 2 317 185 | 7.1 (7.0-7.1) | 4 (0-26) | 60.9 (17.3) | 1 153 342 (49.8) | 1 933 332 (83.4) | 218 774 (9.4) | 148 332 (6.4) | 1 482 673 (64.0) | 630 689 (27.2) |
| Localized | 1 412 462 | 13.3 (13.3-13.4) | 7 (0-29) | 59.8 (16.9) | 771 863 (54.6) | 1 182 255 (83.7) | 127 489 (9.0) | 89 535 (6.3) | 1 170 266 (82.9) | 357 884 (25.3) |
| Metastatic | 301 295 | 0.7 (0.7-0.7) | 1 (0-10) | 64.0 (14.6) | 158 883 (52.7) | 241 681 (80.2) | 35 344 (11.7) | 23 987 (8.0) | 122 231 (40.6) | 88 495 (29.4) |
Abbreviation: PR, fifth to 95th percentile range.
a
Unknown and unstaged categories are not displayed.